Reneo Pharmaceuticals, Inc.
RPHM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $2 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $2 | $1 | $1 |
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | – | – | 100% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | 90.2% |
| EBITDA | $0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | -4,896.1% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | -5,087.3% |
| EPS Diluted | -1.09 | -1.14 | 0 | 1.08 |
| % Growth | 4.4% | – | -100% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |